



## **Poseida to Present P-BCMA-101 Phase 1 Data at the American Association for Cancer Research (AACR) Annual Meeting 2018**

SAN DIEGO, March 26, 2018 (GLOBE NEWSWIRE) -- Poseida Therapeutics Inc. ("Poseida"), a San Diego-based company translating best-in-class gene engineering technologies into lifesaving cell therapies, today announced that initial data from its ongoing P-BCMA-101 Phase 1 study in relapsed/refractory multiple myeloma has been accepted for presentation at the [American Association for Cancer Research \(AACR\) Annual Meeting 2018](#), held April 14-18 in Chicago.

**Presentation Title:** [Clinical trial of P-BCMA-101 T stem cell memory \(Tscm\) CAR-T cells in relapsed/refractory \(r/r\) multiple myeloma \(MM\)](#)

**Presenter:** Eric Ostertag, M.D., Ph.D., Poseida Therapeutics

**Abstract:** CT130

**Date and Time:** 8:00 a.m. - 12:00 p.m. CT, Tuesday, April 17, 2018

### **About P-BCMA-101**

P-BCMA-101 is a CAR-T immunotherapy designed to supercharge a patient's own T cells to safely and effectively eliminate tumor cells carrying B cell maturation antigen (BCMA), which is expressed on essentially all multiple myeloma tumor cells. P-BCMA-101 modifies a patient's T cells using piggyBac™, which enables several desirable features, including:

- **T stem cell memory:** P-BCMA-101 is comprised of an exceptionally high proportion of stem cell memory T cells, resulting in unprecedented durability of response without re-administration of product in multiple preclinical studies.
- **Pure product:** The addition of a human-derived positive selection gene results in a product that is essentially 100% pure in contrast with lentivirus-based products, which are generally 5-30% pure. The higher purity of the product may result in less toxicity.
- **Safety:** piggyBac™ is non-oncogenic and has a safer integration profile than lentivirus. In addition, a human-derived safety switch is added such that P-BCMA-101 can be rapidly attenuated or eliminated if significant side effects occur.

This study is funded in part by the California Institute for Regenerative Medicine. Additional information about the Phase 1 clinical study of P-BCMA-101 is available at [www.clinicaltrials.gov](http://www.clinicaltrials.gov) using identifier: NCT03288493

### **About Poseida Therapeutics, Inc.**

Poseida Therapeutics is translating best-in-class gene engineering technologies into lifesaving cell therapies. The company is developing CAR T-cell immunotherapies for multiple myeloma, prostate and other cancer types, as well as gene therapies for orphan diseases. P-BCMA-101 is Poseida's lead CAR-T therapy currently in Phase 1 clinical development for the treatment of multiple myeloma. Poseida has assembled a suite of industry-leading gene engineering technologies, including the piggyBac™ DNA Modification System, TAL-CLOVER™ and Cas-CLOVER™ site-specific nucleases, and Footprint-Free™ Gene Editing (FFGE). For more information, visit [www.poseida.com](http://www.poseida.com).

### **Corporate Communications Contact:**

Jason Spark

Canale Communications

619-849-6005

[Jason@canalecomm.com](mailto:Jason@canalecomm.com)